Crossmark

Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia

Crossref DOI link: https://doi.org/10.1007/s12094-023-03251-0

Published Online: 2023-06-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ramos Elbal, Eduardo

Fuster, Jose Luis

Campillo, José A.

Galera, Ana María

Cortés, Mar Bermúdez

Llinares, María Esther

Jiménez, Irene

Plaza, Mercedes

Martínez Banaclocha, Helios

Galián, José Antonio

Blanquer Blanquer, Miguel

Martínez Sánchez, María Victoria

Muro, Manuel

Minguela, Alfredo https://orcid.org/0000-0003-2472-5893
Funding

Funding for this research was provided by:

Asociación Pablo Ugarte
License Information

Text and Data Mining valid from 2023-06-27

Version of Record valid from 2023-06-27
More Information

Article History

Received: 20 March 2023

Accepted: 12 June 2023

First Online: 27 June 2023

Declarations

:

: The authors report no conflict of interest.

: The study was performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Written informed consent was obtained from all patients (and/or their parents) in accordance with the Declaration of Helsinki.

Document is current

Any future updates will be listed below